# TACE-HAIC Plus Lenvatinib for Patients With Unresectable HCC: an Open-label, Single-arm, Phase 2 Trial

> **NCT04531228** · NA · UNKNOWN · sponsor: **Yunfei Yuan** · enrollment: 60 (estimated)

## Conditions studied

- Hepatocellular Carcinoma
- Transarterial Chemoembolization

## Interventions

- **PROCEDURE:** TACE-HAIC plus lenvatinib

## Key facts

- **NCT ID:** NCT04531228
- **Lead sponsor:** Yunfei Yuan
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-10-11
- **Primary completion:** 2023-04-30
- **Final completion:** 2023-08-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2021-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04531228

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04531228, "TACE-HAIC Plus Lenvatinib for Patients With Unresectable HCC: an Open-label, Single-arm, Phase 2 Trial". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04531228. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*